n-Lorem Foundation announced a new partnership with Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases.
The BioIndustry Association (BIA) has accused new proposals put forward by the National Institute for Health and Care Excellence (NICE) of being “not fit for purpose” and potentially denying patients from accessing treatments for ultra-rare disease.